“FDA crackdown” headlines can make it sound as though every GLP-1-related product has suddenly been swept into the same category. FDA’s actual 2026 actions are more specific.

The agency has focused on non-FDA-approved compounded GLP-1 drugs that are mass-marketed as alternatives to approved products, misleading advertising, and regulatory conditions that changed after semaglutide and tirzepatide shortages stabilized.

What FDA announced in February 2026

On February 6, FDA announced that it intended to take steps against GLP-1 active pharmaceutical ingredients intended for use in non-FDA-approved compounded drugs that were being mass-marketed as similar alternatives to FDA-approved drugs.

FDA also emphasized advertising. According to the agency, promotional materials for compounded drugs cannot misleadingly present those products as generic versions of FDA-approved drugs, claim they are the same as approved drugs, or make unsupported claims that they are clinically proven to produce the same results.

The shortage rules matter

Compounding policy is closely tied to drug-shortage status. FDA has stated that tirzepatide and semaglutide are not currently on the FDA drug-shortage list, and temporary enforcement-discretion periods associated with the shortages ended in 2025.

What this does NOT mean

• It does not mean FDA has “banned GLP-1s.” FDA-approved GLP-1 medicines remain regulated prescription drugs.
• It does not make every compounded product automatically equivalent to a research-use product.
• It does not mean research peptides, compounded drugs and FDA-approved medicines are interchangeable regulatory categories.

Why the distinction matters

The internet frequently collapses FDA-approved drugs, compounded preparations, active pharmaceutical ingredients and research-use products into one bucket. They are not the same thing. Different laws, manufacturing standards, labeling requirements and enforcement frameworks can apply.

For PepDiscounts, vendor comparisons stay anchored to things we can actually verify: pricing, advertised coupon terms, independent testing documentation, shipping, payment options and vendor policies. Clinical claims belong in clearly identified research/news coverage with primary-source citations.

What to watch next

Expect continued scrutiny of marketing language, especially claims that blur the distinction between non-approved products and FDA-approved medicines. Payment processors, advertising platforms and fulfillment providers can also react to enforcement risk, making this an issue worth watching beyond FDA announcements alone.

Primary sources

• FDA: Intent to Take Action Against Non-FDA-Approved GLP-1 Drugs
• FDA: Compounding policy as GLP-1 supply stabilized

This article is informational and does not provide medical or legal advice.